Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma

Liu,Jian; Wang,Lei; Wang,Tongqing; Wang,Jizheng

doi:10.3892/ol.2018.9145

Expression of IL-23R and IL-17 and the pathology and prognosis of urinary bladder carcinoma

Authors:
- Jian Liu
- Lei Wang
- Tongqing Wang
- Jizheng Wang
View Affiliations

Affiliations: Department of Urology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: July 13, 2018 https://doi.org/10.3892/ol.2018.9145
Pages: 4325-4330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of interleukin-23 receptor (IL-23R) and IL-17 in urinary bladder carcinoma (UBC) was investigated to explore the correlations with prognosis. IL-23/IL-17 axis significantly inhibited the development of inflammatory bowel disease. Thirty patients with UBC were enrolled in Zhengzhou Central Hospital Affiliated to Zhengzhou University from September 2013 to September 2014. Tumor tissue and adjacent healthy tissue were collected, and the levels of IL-23R and IL-17 mRNA were detected by RT-PCR. Thirty healthy people were also selected to serve as normal control group. Serum levels of IL-23R and IL-17 in serum of UBC patients and normal controls were detected by ELISA, and the correlations with clinical features of UBC were analyzed. Pearson's correlation analysis was used to analyze the correlation between IL-23R and IL-17 protein expression. Follow-up study was performed by phone or during patient's visit to out-patient department. Overall survival (OS) and disease-free survival (DFS) curves were plotted by Kaplan-Meier method to analyze the correlation between expression of IL-23R and IL-17 and survival time. ROC curve was used to detect the diagnostic values of IL-23R and IL-17 protein for UBC. Levels of IL-23R and IL-17 mRNA in UBC tissue were 3.26 and 2.65 times higher than those in adjacent tissue (P<0.05), and serum levels of IL-23R and IL-17 protein in UBC patients were significantly higher than those in normal control group. Protein expression levels of IL-23R and IL-17 were correlated with clinical stage and lymph node metastasis in UBC patients (P<0.05), and Cox hazard model showed that L-23R and IL-17 expression may be independent factors for UBC (P<0.05), and high expression levels of IL-23R and IL-17 significantly shortened the OS and DFS (P<0.05). Serum levels of IL-23R and IL-17 can be used to effectively diagnose clinical stage and lymph node metastasis of UBC patients, and the combined diagnosis has a higher sensitivity and specificity than the diagnosis using a single factor. These findings indicated that expression levels of IL-23R and IL-17 were increased in tumor tissue and serum of UBC patients, and the increased expression levels of IL-23R and IL-17 were correlated with poor prognosis. Detection of IL-23R and IL-17 levels has certain clinical significance in the diagnosis and prognosis of UBC.

View Figures

View References

1	Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E and Taieb J: Colorectal cancer and immunity: What we know and perspectives. World J Gastroenterol. 20:3738–3750. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ikemoto T, Shimada M, Ishikawa D, Teraoku H, Yoshikawa M, Yamada S, Takasu C, Saito Y, Morine Y and Imura S: The clinical impact of CD4⁺ CD49b⁺ regulatory T cells addition to FOXp3⁺ regulatory T cells in cancer patients' immunity. J Am Coll Surg. 221:e222015. View Article : Google Scholar
3	Zhong Z, Sanchez-Lopez E and Karin M: Autophagy, inflammation, and immunity: A troika governing cancer and its treatment. Cell. 166:288–298. 2016. View Article : Google Scholar : PubMed/NCBI
4	Chang WJ, Du Y, Zhao X, Ma LY and Cao GW: Inflammation-related factors predicting prognosis of gastric cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI
5	Shalapour S and Karin M: Immunity, inflammation, and cancer: An eternal fight between good and evil. J Clin Invest. 125:3347–3355. 2015. View Article : Google Scholar : PubMed/NCBI
6	Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al: Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science. 344:641–645. 2014. View Article : Google Scholar : PubMed/NCBI
7	Chen DS and Mellman I: Oncology meets immunology: The cancer-immunity cycle. Immunity. 39:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
8	Yan J, Smyth MJ and Teng MWL: Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb Perspect Biol. Jul 17–2017.(Epub ahead of print).
9	Stanilov N, Miteva L, Deliysky T, Jovchev J and Stanilova S: Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Lab Med. 41:159–163. 2010. View Article : Google Scholar
10	Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, et al: IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522:345–348. 2015. View Article : Google Scholar : PubMed/NCBI
11	Lin Q, Xue L, Tian T, Zhang B, Guo L, Lin G, Chen Z, Fan K and Gu X: Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer. Int J Biol Markers. 30:e359–e363. 2015. View Article : Google Scholar : PubMed/NCBI
12	Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M and Al-Dacak R: Targeting the tumor microenvironment: The protumor effects of IL-17 related to cancer type. Int J Mol Sci. 17:E14332016. View Article : Google Scholar : PubMed/NCBI
13	Iwakura Y and Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest. 116:1218–1222. 2006. View Article : Google Scholar : PubMed/NCBI
14	Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M and Fouser LA: Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 203:2271–2279. 2006. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Sica A, Allavena P and Mantovani A: Cancer related inflammation: The macrophage connection. Cancer Lett. 267:204–215. 2008. View Article : Google Scholar : PubMed/NCBI
17	Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, et al: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
18	Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K and Yamamoto K: IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 179:7128–7136. 2007. View Article : Google Scholar : PubMed/NCBI
19	Punt S, Fleuren GJ, Kritikou E, Lubberts E, Trimbos JB, Jordanova ES and Gorter A: Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer. OncoImmunology. 4:e9845392015. View Article : Google Scholar : PubMed/NCBI
20	Straus DS: TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. Mol Cancer. 12:782013. View Article : Google Scholar : PubMed/NCBI
21	Bagheri N, Azadegan-Dehkordi F, Shirzad H, Rafieian-Kopaei M, Rahimian G and Razavi A: The biological functions of IL-17 in different clinical expressions of Helicobacter pylori-infection. Microb Pathog. 81:33–38. 2015. View Article : Google Scholar : PubMed/NCBI
22	Li L and Boussiotis VA: The role of IL-17-producing Foxp3⁺CD4⁺ T cells in inflammatory bowel disease and colon cancer. Clin Immunol. 148:246–253. 2013. View Article : Google Scholar : PubMed/NCBI
23	Helbling M, Lukesch A, Haimovici A, Karamitopoulou E, Berger MD, Hädrich M, Mallaev M, Schnüriger B, Koelzer VH, Dawson H, et al: Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: A retrospective multicenter study of 675 patients. Oncotarget. 5:4671–4682. 2014. View Article : Google Scholar : PubMed/NCBI
24	Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, Chen C, Huang M, Chen J, Wu W, et al: Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer. Am J Transl Res. 8:2255–2264. 2016.PubMed/NCBI